Therapeutic targets to reduce cardiovascular disease in type 2 diabetes (Q37464731)

20 August 2017

1 reference

title

Therapeutic targets to reduce cardiovascular disease in type 2 diabetes (English)

1 reference

20 August 2017

0 references

cardiovascular disease

1 reference

Cyrus DeSouza

1

1 reference

20 August 2017

Vivian Fonseca

series ordinal

2

1 reference

20 August 2017

publication date

1 May 2009

1 reference

Nature Reviews Drug Discovery

20 August 2017

published in

1 reference

20 August 2017

volume

8

1 reference

20 August 2017

issue

5

1 reference

20 August 2017

page(s)

361-367

1 reference

Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases.

20 August 2017

cites work

1 reference

Inflammatory mechanisms in the regulation of insulin resistance

21 January 2018

1 reference

Emerging roles of SIRT1 in vascular endothelial homeostasis

21 January 2018

1 reference

Regional haemodynamic responses to pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide in conscious rats

21 January 2018

1 reference

The role of the endocannabinoid system in atherosclerosis.

21 January 2018

1 reference

Diabetes and decline in heart disease mortality in US adults.

21 January 2018

1 reference

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

31 March 2020

1 reference

The 10-year post-trial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in context

31 March 2020

1 reference

10-year follow-up of intensive glucose control in type 2 diabetes

31 March 2020

1 reference

Images in clinical medicine. Paget's disease of the mandible

31 March 2020

1 reference

Glucose control and vascular complications in veterans with type 2 diabetes

31 March 2020

1 reference

Effects of intensive glucose lowering in type 2 diabetes

31 March 2020

1 reference

Cardiovascular diabetology: clinical, metabolic and inflammatory facets. Preface

31 March 2020

1 reference

New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond

31 March 2020

1 reference

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

31 March 2020

1 reference

Cardiovascular effects of sulphonylureas: role of K(ATP) channels

31 March 2020

1 reference

Intensive insulin treatment in type 2 diabetes

31 March 2020

1 reference

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

31 March 2020

1 reference

Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes?

31 March 2020

1 reference

Inflammation and insulin resistance

31 March 2020

1 reference

Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease

31 March 2020

1 reference

Endothelial function and inflammation in coronary artery disease

31 March 2020

1 reference

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

31 March 2020

1 reference

Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting

31 March 2020

1 reference

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

31 March 2020

1 reference

Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines

31 March 2020

1 reference

Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride

31 March 2020

1 reference

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

31 March 2020

1 reference

Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity

31 March 2020

1 reference

Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug

31 March 2020

1 reference

Recovery from heat shock injury by activation of Na -glucose cotransporter in renal epithelial cells

31 March 2020

1 reference

Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na( )-glucose cotransporter inhibitor T-1095

31 March 2020

1 reference

A functional role for sodium-dependent glucose transport across the blood-brain barrier during oxygen glucose deprivation

31 March 2020

1 reference

Human cardiomyocytes express high level of Na /glucose cotransporter 1 (SGLT1)

31 March 2020

1 reference

Post-prandial hyperglycaemia and prevention of cardiovascular disease.

31 March 2020

1 reference

Nuclear factor-kappa B: from clone to clinic

31 March 2020

1 reference

Activation of nuclear factor kappaB as a target for anti-inflammatory therapy

31 March 2020

1 reference

Salsalate improves glycemia and inflammatory parameters in obese young adults

31 March 2020

1 reference

The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia

31 March 2020

1 reference

Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist

31 March 2020

1 reference

Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis

31 March 2020

1 reference

Mammalian sirtuins--emerging roles in physiology, aging, and calorie restriction

31 March 2020

1 reference

Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes

31 March 2020

1 reference

SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes

31 March 2020

1 reference

Sirt1 modulates premature senescence-like phenotype in human endothelial cells

31 March 2020

1 reference

Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice

31 March 2020

1 reference

Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity?

31 March 2020

1 reference

Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.

31 March 2020

1 reference

11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice

31 March 2020

1 reference

The Development of INT131 as a Selective PPARgamma Modulator: Approach to a Safer Insulin Sensitizer

31 March 2020

1 reference

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

31 March 2020

1 reference

Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes

31 March 2020

1 reference

Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk

31 March 2020

1 reference

PACAP in the glucose and energy homeostasis: physiological role and therapeutic potential

31 March 2020

1 reference

Cardioprotective role of the VIP signaling system

31 March 2020

1 reference

G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes.

31 March 2020

1 reference

Down-regulation of vasoactive intestinal peptide and altered expression of its receptors in rat diabetic cardiomyopathy

31 March 2020

1 reference

Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations

31 March 2020

1 reference

Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications

31 March 2020

1 reference

Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages

31 March 2020

1 reference

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial

31 March 2020

1 reference

Depression and anxiety with rimonabant

31 March 2020

1 reference

Glucokinase activators for the potential treatment of type 2 diabetes

31 March 2020

1 reference

Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor.

31 March 2020

1 reference

Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle

31 March 2020

1 reference

Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study

31 March 2020

1 reference

Non-insulin antidiabetic therapy in cardiac patients: current problems and future prospects

31 March 2020

1 reference

12 December 2020

Chronic resveratrol enhances endothelium-dependent relaxation but does not alter eNOS levels in aorta of spontaneously hypertensive rats

1 reference

12 December 2020

Metformin as first choice in oral diabetes treatment: the UKPDS experience.

1 reference

12 December 2020

PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.

1 reference

12 December 2020

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

12 December 2020

Molecular and functional characterization of pituitary adenylate cyclase-activating polypeptide (PACAP-38)/vasoactive intestinal polypeptide receptors in pancreatic beta-cells and effects of PACAP-38 on components of the insulin secretory system

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD2872

1 reference

20 August 2017

1 reference